Medication info
Namuzol Tablet (Terbinafine Hydrochloride)

Namuzol Tablet (Terbinafine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
JW Pharmaceutical Corp.
Appearance
White round tablets
Packaging
30 tablets, 100 tablets/bottle
Approval status
Active

MFDS item code 200102644 · Notified 2001.01.10 · Insurance code 644100040

Summary

Main use
Treatment of onychomycosis and skin fungal infections (e.g., tinea pedis), and tinea capitis
Who takes it
Adults · Children
Adult dose
Administer terbinafine 125 mg per dose twice daily or 250 mg per dose once daily. The duration of treatment according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Usually administer for 6 weeks~3 months. For infections of the fingernails or relatively small toenails, the treatment duration may be shortened to 3 months or less. A treatment duration of 3 months is usually sufficient for toenail infections, although some patients may require 6 months or longer. Treatment may take longer in patients with slow nail growth. For patients with creatinine clearance below 50 mL per minute, reduce the daily dose by 1/2.
Child dose
Administer to children aged 2 years and older. Use is not recommended in children under 2 years of age because there is no experience with administration in this age group. Tinea capitis: 4 weeks Tinea capitis occurs primarily in children. To prevent recurrence of infection, treatment should be administered regularly for the appropriate prescribed duration. For infections of the fingernails or relatively small toenails, or in younger patients, the treatment duration may be shortened to 3 months or less. Body weight below 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Because experience with administration is limited, the decision to administer should be made after considering the benefits and risks of treatment. Body weight 20~40 kg (5 to 12 years): Administer 125 mg per dose once daily. Body weight above 40 kg (over 12 years): Administer 250 mg per dose once daily.

Ingredients

Manufacturer
JW Pharmaceutical Corp.

Efficacy & effects

Treatment of onychomycosis and skin fungal infections (e.g., tinea pedis), and tinea capitis

  • Skin fungal infections
  • athlete's foot
  • body ringworm
  • tinea capitis
  • onychomycosis
View approved original text

This medicine is used to treat skin fungal infections and onychomycosis caused by dermatophytes, such as athlete's foot, body ringworm, and tinea capitis in adults. Additionally, it is effective for treating tinea capitis in children. This drug helps improve various skin and nail fungal infections.

How to take

Adult dose

Administer terbinafine 125 mg per dose twice daily or 250 mg per dose once daily. The duration of treatment according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Usually administer for 6 weeks~3 months. For infections of the fingernails or relatively small toenails, the treatment duration may be shortened to 3 months or less. A treatment duration of 3 months is usually sufficient for toenail infections, although some patients may require 6 months or longer. Treatment may take longer in patients with slow nail growth. For patients with creatinine clearance below 50 mL per minute, reduce the daily dose by 1/2.

Child dose

Administer to children aged 2 years and older. Use is not recommended in children under 2 years of age because there is no experience with administration in this age group. Tinea capitis: 4 weeks Tinea capitis occurs primarily in children. To prevent recurrence of infection, treatment should be administered regularly for the appropriate prescribed duration. For infections of the fingernails or relatively small toenails, or in younger patients, the treatment duration may be shortened to 3 months or less. Body weight below 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Because experience with administration is limited, the decision to administer should be made after considering the benefits and risks of treatment. Body weight 20~40 kg (5 to 12 years): Administer 125 mg per dose once daily. Body weight above 40 kg (over 12 years): Administer 250 mg per dose once daily.

Precautions

This medication is generally not recommended for patients with chronic or active liver disease. Before administration, ensure a review of the patient's history of liver disease and current condition. Regular liver function tests should be performed before treatment initiation and during treatment, as liver problems may arise. If symptoms of liver dysfunction (e.g., persistent nausea, loss of appetite, fatigue, vomiting, pain in the upper right abdomen, jaundice, etc.) occur, inform the physician immediately, and discontinue the medication. This medication should not be used in patients with blood disorders, severe renal failure, infants under 2 years old, nursing mothers, etc. Additionally, it should not be administered to those with known allergies to this medication or its components. Patients with impaired renal function, elderly individuals, or underweight children should use this medication with caution, and should stop taking it immediately if severe skin reactions occur. Liver function and blood test results should be monitored periodically while using this medication, and if unusual symptoms like myalgia, arthralgia, skin rash, dizziness occur, consult a physician. Dizziness may occur while driving or operating machinery, so caution is advised. This medication may interact with other drugs, so patients should inform healthcare providers of any other medications they are taking, and dosage adjustments may be necessary. Women who are pregnant or may become pregnant should carefully consider the risks and benefits before taking this medication, and nursing mothers should discontinue breastfeeding while on this medication. In case of overdose, symptoms like headache, nausea, abdominal pain, dizziness may arise, and immediate medical attention should be sought for appropriate treatment. This medication should be stored out of reach of children, away from direct sunlight, and at room temperature.

Side effects

Liver and gallbladder failure, hepatitis, bile duct obstruction, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, fatigue, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, subcutaneous hemorrhage, leukopenia, anemia, rash, itching, photosensitivity reaction, mucocutaneous syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, bullous dermatitis, psoriasiform rash, exacerbation of psoriasis, hair loss, musculoskeletal reaction, arthralgia, myalgia, weakness, elevated CPK, elevated myoglobin, hypotension, shortness of breath, chest tightness, urticaria, erythema, facial edema, lymphangiectasia, abdominal distension, decreased appetite, dyspepsia, nausea, mild abdominal pain, diarrhea, discomfort in the stomach, thirst, vomiting, glossitis, depression, anxiety, headache, taste disturbance, dizziness, drowsiness, sensory abnormalities, decreased sensation, decreased attention, insomnia, elevated BUN, frequent urination, visual disturbances, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated total cholesterol in blood, elevated triglycerides, fatigue, discoloration of the tongue, palpitations, edema, menstrual irregularities, paralysis, systemic disorder, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, decreased vision, hearing loss, auditory impairment, vasculitis, permanent loss of smell, anosmia, hyposmia, drug rash associated with eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, increased blood creatine phosphokinase

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can be sensitive to moisture and air, so it must be stored in a tightly sealed container. The recommended storage temperature is between 1 to 30 degrees Celsius at room temperature to help maintain its efficacy.

Appearance and packaging

Appearance

White round tablets

Package unit

30 tablets, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.